Practical Guide 2017

Our readership explodes: we have new projects, we need help! we are looking for translators and also voices for podcasts. Someone to animate via social networks would also be of great help! You like this blog, so, please help!

This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

Here is an exchange, a rather bad one ... One says:
This is called 'close the door behind you', much like former immigrants opposing ... immigration. And there is worse: each and every one has his own restrictions, taboos: according to them, descalation is not for you if CD4 are less than ... If your CD4/CD8 ratio is less than ... If your reservoir is... If your combo is not X or Y ... Etc. All this is rigorously FALSE!

Without an informed, well-argued deciphering, it sparks in all directions: this is all FAKE-NEWS

A Practical Guide to Avoid Misunderstanding

Update of the Practical Guide SAFE 4/7: ANRS-4D introduces a PREMIUM eligibility and the Morlat 2016-2017 report explicitly authorizes ICCARRE, without any practical information, without citing all the trials, which would have been useful and honest. There is a great advantage: by saying nothing, it saves us the usual bullshit! Pr Rouzioux-of-criteria ate her hat!

The Morlat report is the usual useful idiot, silly and useless, unusable and unpractical. The reader, patient or doctor, is referred to just 2 trials, without the least bibliographic reference to ICCARRE. Morons!

This suits me a little, the patient searches on the internet and invariably gets to the Practical Guide, a very downloaded document, and for medical advise, on our list of doctors. She's out of trouble! Good!

The Practical Guide is enriched accordingly. It is available in French, English, Portuguese, Spanish (soon) and Arabic (indeed. It is not claimed to be perfect, nor to be a substitute to a doctor, expert-in-that-very-matter (Beware of incapable, ignorant, incompetent or liars and ... counterfeits)

The 2016 version differs from the 2015 version:

ANRS-4D revolutionizes the short cycle; The 2016 version therefore differs from the 2015 version:
- Eviplera® (Complera®) is tested: 100% successful
- Premium eligibility: Short Cycle is more appealing
- Direct to 4/7, under eligibility conditions: validated
- In patients, strictly eligible and strictly observant, the VL has never picked up: in this context, our rule of frequent VL can reasonably be reconsidered (even if I keep liking it, but I am incapable to prove it is indispensible

Looking at at the rare (very very rare ...) personal testimonies of failures, one inevitably finds failure to follow of one of the three rules: Efficiency, progressivity, frequent VL. And Shit happens ... Well, always easy repaired (eg back to 7/7) ...

Premium Eligibility

Progressivity: Well ... I prefer progressivity, because I went through the anguish of 6/7 (I was scared!). Perhaps useless, it did not cost me.

Frequent VLs: People have trouble with this; VLs detect a loss of efficiency as soon as possible. It is the other side of the efficiency coin. If one is sure of the efficacy, very sure, what about the need for frequent VLs (month-1, m-2, m-4, m-6 ...)? Okay... But true efficiency is proved with ... VL!

Efficiency: many presume drug's efficiency ... Yes, they have been given the latest very modern, very pricey, so well marketed that they neglected all warnings. This medicine, imperfect, is better sent to the sewer. ANRS-4D formalizes the Premium eligibility, which is already in ICCARRE (if you can decypher), not in the others, an additional proof that ICCARRE is not a simple sequel.

conditions	Simple Eligibility	Premium Eligibility
a priori efficiency validation	No	Yes (genotype required)
validation of usage efficacy	2 successives UD VL	3 times VL < 50 (make sure it is undetectable)
minimal duration of current ART	12 months	4 months
Advantages	no Genotype	4/7 direct frequent VL unnecessary?
disadvantages	6/7, 5/7; frequent VL	Genotype required or redone

ICCARRE method of to redo a genotype or regain sensitivity is stunning! It is a Septist's nightmare and,therefore a good reason to explore it! And we'll get back to it!

What about ANRS-170-Quatuor?

Announced for the end of 2016, then by act-up for July 2017, it will be good enough if it ever starts one day! We are being put off. Results for 2020! At best ... Well ... I hope noone is fooled by this little game.

It is merely the continuation of the ANRS-4D trial, which coordination had been entrusted to Mmes BENALYCHERIF and AMAT (phone: +33 (0)1 40 25 63 65, email: aida.benalycherif... followed the at sign then by ...gmail.com et karine.amat... followed the at sign then by ...hotmail.fr). You should be able to find more there.

Morlat already authorizes ICCARRE, then, what is the point with ANRS-170-Quatuor? What's the point?

This blog is not a medical advice: For this strategy, see Dr. de Truchis (see list). What about others? Well ... Why the copy when we have the original? Ignore the ignorant, and go to one of these docs, Practical Guide in hand. Move your ass! And report!

Today, is the first of Ramadan: our elders have understood the benefit of 'breaks', also of the Shabbat breaks. Since Copernicus, we have a much better understanding of rhythms! Good Ramadan to those who celebrate it, and Good Shabbat and Good fuck to all the others!

Our readership explodes: we have new projects, we need help! we are looking for translators and also voices for podcasts. Someone to animate via social networks would also be of great help! You like this blog, so, please help!

This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

First-line Tivicay Monotherapy

First-line Tivicay Monotherapy
This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

First-line with Mono-DTG

By Charles Edouard!

Here is a topical question:

For medical advice, see Pr Katlama or Dr. Lanzafame. What do the tests say? In monotherapy, in ING 111521, 90% of patients passed the <400 mark in just 10 days! Lanzafame initiates the Tivicay ® monotherapy, from the first prescription. As first-line, DTG + 3TC Bitherapy worked well. The proposals DTG + 3TC or Tivicay ® + Truvada ® are not coformulated: they allow monotherapy: just leave the other one in the closet. Dr. Lafeuillade recounts a personal experiment ...

Will the Wainberg hypothesis be validated by Lanzafame?

On a 'wild' (non-mutated) virus, the first mutation to appear is R263K. But it prevents the virus from regaining strength (loss of fitness), and, the reservoir should 'normally' decrease: it falls into a Darwinian black hole .... Adios asshole!

Conversely, if the virus has step-stone mutations or substitutions (I simplify), it can acquire resistance mutations; The benefit of R263K is lost, and that of mono-Tivicay® as well ...

If the Wainberg concept is correct, then, we should see at the clinic:
- a rate of success not too bad, not too good, on already mutated viruses (eg failure to RAL or EVG), and this is what we observe (Viking trial)
- a success rate, in maintenance monotherapy, which depends on the presence of the footsteps: this is what is observed in the BMM + P cohort: it is the Achille's heel.
- an excellent success rate, in first-line on wild type virus: this is what we observe (ING test 111521 + Lanzafame report)

If the Wainberg / Mesplede theory (the R263K pathway is beneficial) is accurate, the success of DTG monotherapy should not depend on any parameter other than wild-type (or not) nature.

Tivicay® Monotherapy with Naïve Patients: Yessss!

Hence the importance of the latest publication by Dr. M. Lanzafame, who further increased his group of patients using Tivicay® monotherapy as their first therapy (wild virus and a VL <100.000).

Lanzafame saves the medical honor ... and the world!

He has redone ING 111521: it is a prudent scientific approach, to confirm the results of a commercial trial... This is in line with the result of ING 111521, unexpected at first, then put under the rug or even occulted later.

He chooses his patients, with restrictive conditions on the virus, the 'wildest' possible. And none on CD4: one patient had CD4 = 1, another CD4 = 2!

Lanzafame unveils a new strategy. His patients (why not you?) will therefore benefit from an effective monotherapy, as first line, which opens the door to an alleviation like ICCARRE 4/7. His group will be able to move closer to remission ('cure').

He invites us to reconsider the results of BMM + P (Barcelona, ​​Montreal, Munich) + Paris, where, with selected patients, we have excellent results, contrary to the DOMONO protocol, where patients are not or poorly chosen, and where the result is mediocre.

Obviously, no one told you about this !! If the ignorants and traitors tell you that mono-Tivicay® does not exist, well, now you know that it does... The subject is relaunched from the ethical, clinical, public health angle: we will discuss this soon ...

This blog is not a medical advice: For this strategy, get in touch with Dr Katlama, Lafeuillade or Lanzafame (see list). What about others? Well... They are lagging behind, so you ignore the ignorant, and you go to one of these 3 doctors. Move your ass! And report here!

In this election weekend many will have to swallow a bitter snake...
Not me! This weekend is my first without meds: it is the first of my return to 1/14! And it is real cool!

Comments

Nanar May 21, 2017


Charles-Edouard! May 21, 2017



This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

beyond 1/7

This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

The other side of the 1/7 mirror

By Charles Edouard!

A tribute to Patrick Valas, the first ICCARRE blogger: the only known mention on better than 1/7!

Dixit Leibowitch:

They dreamed of it, Charles-Edouard did it!

The Eclipse lasts ... from 7 to 35 (*) j ... Thus ...

# intake  1 / X   VL   1 7   <20   2 9 3 9 4 9 5 9 6 9 7 9 8 11   <20   9 11 10 11 11 11   <20   12 11 13 11 14 12   <20   15 11 16 11   <20   17 14 18 13   <20   19 14 20 15   <20   21 14 22 14   <20   23 14 24 14 25 15   <20   26 16 27 17   <20   28 17 29 19   <20   30 22   <20   31 20 32 22   <20   33 27 20<VL<200

Obviously, protocolization implies that we limit ourselves to 1/7 ... Yes, but Leibowitch's recipe is a MOAB (mother of all bombs)! And it works wonders. When one is in the right alignment of stars, that one is not bound to the injunctions of the Master, that one writes regularly on 4/7, 1/7, well, one asks necessarily the question: what about beyond 1/7: Exactly as Leibowitch evoked it; 2 or 1/10, then on 14, etc ... We will go to look for the limits of our own system, and then adjust. Its miracle is the Eclipse He or She, infedded or not even concerned, does not rule: the Virus is the sole decider, it rules as an absolute master, and its miracle is the Eclipse! As long as the Virus does not go up, it does not go up: it's just as simple as that. There is no known reliable predictor, not even proviral DNA as demonstrated, conversely, CHUN in Toronto: moreover we don't give a damn: you measure the Eclipse, then YOU decide. The table opposite is my ICCARRE schedule beyond 1/7, with 1/X going on, without the slightest blip, up to 1/22, easy... Beyond, at 1/27, it trips... Fine ... We make a note... The 190 eligible and observing patients have ZERO intrinsic failures at 4/7, and now we quibble to launch the QUATUOR trial! With this experiment, I learned a lot... In retrospect, I should have done an analytical interruption, with a weekly step: Ananworanich tells us that the average is at approx. 21 j. (*): I'm just an average patient! Nothing special! And this was before Dolutegravir (Tivicay ®) arrival which opens new horizons.

Well ... So when I 'm being told that I'm in tow behind Leibowitch, it makes me smile ... This is no beauty contest. It is a strategy based on observable facts: I have an eclipse of a little less than a month, so I set the cursor at 15 days.

With the good old patent, I made almost an entire year at 1/14 and better, just count the days on the table ;-)

I passed the 6 months beacon with the wonderful Tivicay® 50mg + 3TC 300mg: 5 months on Sat. + Sun and 1 month on Sundays, double dose: always <20!

We are May 1st and I try again at 1/15, ie, Remission-24 (I will explain ...) with a whole new method.

What to do with the advice of good old Pr. Péronne, who orders to wait for the end of that trial, then for the next one, and then whatever else? I plug them where they deserve to be!

Happy MayDay, good fuck, and not too many meds! OK?


This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.